Beijing Tong Ren Tang Chinese Medicine Company Limited

SEHK:3613 株式レポート

時価総額:HK$7.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Beijing Tong Ren Tang Chinese Medicine マネジメント

マネジメント 基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Wang Chi

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間less than a year
CEOの所有権n/a
経営陣の平均在職期間less than a year
取締役会の平均在任期間1.8yrs

経営陣の近況

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03
Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28
A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12
Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29
Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28
Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25
Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27
Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28
Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11
Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04
What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18
Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11
Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

CEO(最高経営責任者

Wang Chi (49 yo)

less than a year

在職期間

Mr. Wang Chi is Executive Director and Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited from May 10, 2024. Mr. Chi has experience in Medical and Pharmaceutical industry. Mr...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Hai Ou Gu
Executive Chairman of the Boardless than a yearデータなしデータなし
Fei Chen
Executive Director & Executive Deputy GMless than a yearHK$975.00k0.0051%
HK$ 399.7k
Wang Chi
CEO & Executive Directorless than a yearデータなしデータなし
Fung Yi Tsang
CFO & Company Secretary4.1yrsデータなしデータなし
Zheng Guo Shen
Deputy GM & General Counselno dataデータなしデータなし

0.3yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: 3613の経営陣は 経験豊富 とはみなされません ( 0.3年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Hai Ou Gu
Executive Chairman of the Boardless than a yearデータなしデータなし
Fei Chen
Executive Director & Executive Deputy GM4.3yrsHK$975.00k0.0051%
HK$ 399.7k
Wang Chi
CEO & Executive Directorless than a yearデータなしデータなし
Yok-Sing Tsang
Independent Non-Executive Director6.8yrsHK$288.00kデータなし
Ngai Chi Chan
Independent Non-Executive Director11.2yrsHK$288.00kデータなし
Li Feng
Non-Executive Director1.8yrsデータなしデータなし
Hong Xi Xu
Independent Non-Executive Director1.3yrsHK$240.00kデータなし

1.8yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: 3613の 取締役会経験豊富 ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。